A Phase II Study of Anlotinib in MTC Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Tumor
Interventions
DRUG

Anlotinib

Trial Locations (10)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

Unknown

Peking Union Medical College Hospital, Beijing

The first hospital affiliated to fujian medical university, Fuzhou

Gansu Province Tumor Hospital, Lanzhou

Sun Yat-Sen University Cancer Center, Guozhou

Harbin medical university affiliated tumor hospital, Harbin

Jiangsu province tumor hospital, Nanjing

Liaoning Province Tumor Hospital, Shenyang

Cancer Hospital of Fudan University, Shanghai

Tianjin Medical University Cancer Hospital, Tianjin

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY